Since its inception in 2010, evitria is a biotech service provider focused on the transient expression of recombinant antibodies in CHO cells. This long-standing and deep focus allows the company to deliver antibodies of exceptional quality with outstanding service levels concerning turnaround time and material quantity. With a track record of more than 75,000 transfections performed and more than 12,000 antibody-based molecules purified, evitria is a trusted partner for full outsourcing of antibody production for research purposes, to manage capacity bottlenecks, or to pursue single projects.
Following evitria’s recent financing round in 2018, Afinum and SHS Capital became the majority stakeholders in the company. The two German investment firms are selling their shares to Stockholm-based biomedical research company Atlas Antibodies, a leading, global developer of advanced reagents for biomedical research.
Commenting on the acquisition, Torben Jørgensen, Chairman of Atlas Antibodies, said: “This transaction brings together two highly innovative companies with top quality solutions in their respective niches in the industry of antibodies. We are excited to support Christian Eberle and the evitria team to continue to grow their business, and for Atlas Antibodies and evitria to work together in close partnership to capture the opportunities inherent in this combined platform.”
Christian Eberle, CEO of evitria, comments: “After successfully building and continuously improving our expression platform over the last ten years, we look forward to this next phase in our company’s development. We have only recently started to more actively pursue opportunities on a global basis, and look forward to continuing on this growth journey backed by the team around Atlas Antibodies and Patricia Industries.”
(Press release/RAN)
Please login or sign up to comment.
Commenting guidelines